-
Je něco špatně v tomto záznamu ?
Citrate anticoagulation control by ionized calcium levels does not prevent hemostasis and complement activation during hemodialysis
Opatrný K, Richtrová P, Polanská K, Wirth J, Sefrna F, Brandl M, Falkenhagen D
Jazyk angličtina Země Spojené státy americké
Typ dokumentu klinické zkoušky
NLK
Medline Complete (EBSCOhost)
od 1998-01-01 do Před 1 rokem
Wiley Online Library (archiv)
od 1997-01-01 do 2012-12-31
- MeSH
- aktivace komplementu účinky léků MeSH
- aktivace trombocytů účinky léků MeSH
- antikoagulancia farmakologie MeSH
- citráty farmakologie MeSH
- dialýza ledvin MeSH
- dospělí MeSH
- financování organizované MeSH
- hemokoagulace účinky léků MeSH
- lidé středního věku MeSH
- lidé MeSH
- počet leukocytů MeSH
- senioři MeSH
- trombóza prevence a kontrola MeSH
- vápník krev terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- klinické zkoušky MeSH
The purpose of this study was to determine whether or not regional citrate anticoagulation (RCA) controlled by ionized calcium (iCa(2+)) would overcome thrombogenicity, prevent hemostasis, and complement activation during hemodialysis (HD). RCA was performed in 10 patients during 10 HD sessions using a polysulfone membrane in an effort to keep iCa(2+) at dialyzer outlet at < or =0.4 mmol/L. Compared to baseline, plasma levels of thrombin-antithrombin III complexes rose significantly at 240 min, and tissue factor and complement C5a component levels at 30 and 240 min of the procedure. Thrombocyte count declined significantly at 30 and 240 min, while activated clotting time (ACT) did not increase significantly, and platelet factor 4 as well as von Willebrand factor levels did not alter significantly. While ACT correlated significantly with some thrombogenicity markers, iCa(2+) did not correlate with ACT, changes in hemostasis, or C5a. We conclude the usually recommended iCa(2+) levels in the HD extracorporeal circuit did not guarantee the complete overcoming of thrombogenicity, prevention of hemostasis, and complement activation.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07527922
- 003
- CZ-PrNML
- 005
- 20250121143652.0
- 008
- 090830s2007 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Opatrný, Karel, $d 1954-2006 $7 nlk19990073633
- 245 10
- $a Citrate anticoagulation control by ionized calcium levels does not prevent hemostasis and complement activation during hemodialysis / $c Opatrný K, Richtrová P, Polanská K, Wirth J, Sefrna F, Brandl M, Falkenhagen D
- 314 __
- $a Department of Internal Medicine I, Charles University Medical School, Alej Svobody 80, 304-60 Pilsen, Czech Republic
- 520 9_
- $a The purpose of this study was to determine whether or not regional citrate anticoagulation (RCA) controlled by ionized calcium (iCa(2+)) would overcome thrombogenicity, prevent hemostasis, and complement activation during hemodialysis (HD). RCA was performed in 10 patients during 10 HD sessions using a polysulfone membrane in an effort to keep iCa(2+) at dialyzer outlet at < or =0.4 mmol/L. Compared to baseline, plasma levels of thrombin-antithrombin III complexes rose significantly at 240 min, and tissue factor and complement C5a component levels at 30 and 240 min of the procedure. Thrombocyte count declined significantly at 30 and 240 min, while activated clotting time (ACT) did not increase significantly, and platelet factor 4 as well as von Willebrand factor levels did not alter significantly. While ACT correlated significantly with some thrombogenicity markers, iCa(2+) did not correlate with ACT, changes in hemostasis, or C5a. We conclude the usually recommended iCa(2+) levels in the HD extracorporeal circuit did not guarantee the complete overcoming of thrombogenicity, prevention of hemostasis, and complement activation.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antikoagulancia $x farmakologie $7 D000925
- 650 _2
- $a hemokoagulace $x účinky léků $7 D001777
- 650 _2
- $a vápník $x krev $x terapeutické užití $7 D002118
- 650 _2
- $a citráty $x farmakologie $7 D002951
- 650 _2
- $a aktivace komplementu $x účinky léků $7 D003167
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a počet leukocytů $7 D007958
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a aktivace trombocytů $x účinky léků $7 D015539
- 650 _2
- $a dialýza ledvin $7 D006435
- 650 _2
- $a trombóza $x prevence a kontrola $7 D013927
- 655 _2
- $a klinické zkoušky $7 D016430
- 700 1_
- $a Richtrová, Pavlína, $d 1975- $7 xx0074467
- 700 1_
- $a Polanská, Kamila $7 xx0098547
- 700 1_
- $a Wirth, Jan $7 xx0123183
- 700 1_
- $a Šefrna, František $7 xx0179993
- 700 1_
- $a Brandl, Martin $7 xx0327927
- 700 1_
- $a Falkenhagen, Dieter, $d 1942-2015 $7 xx0215077
- 773 0_
- $w MED00000595 $t Artificial organs $g Roč. 31, č. 3 (2007), s. 200-207 $x 0160-564X
- 910 __
- $a ABA008 $b x $y 9 $z 0
- 990 __
- $a 20090824163150 $b ABA008
- 991 __
- $a 20250121143648 $b ABA008
- 999 __
- $a ok $b bmc $g 672952 $s 532197
- BAS __
- $a 3
- BMC __
- $a 2007 $b 31 $c 3 $d 200-207 $i 0160-564X $m Artificial organs $x MED00000595
- LZP __
- $a 2009-B4/vtme